| MMUD (N = 280) | CBT (N = 902) | p value |
---|---|---|---|
Follow-up (reverse KM, months) | |||
Median (IQR) | 19.1 (11.4–36.7) | 46.8 (22.6–72.6) | < 0.001 |
Patient age (years) | Â | Â | Â |
Median (min–max) [IQR] | 52.1 (18.2–75.6) [39.9–61.2] | 50.5 (18.1–73.2) [38.4–60.3] | 0.087 |
Year transplant | |||
Median (min–max) [IQR] | 2017 (2010–2019) | 2013 (2010–2019) | < 0.001 |
Cytogenetics risk groupa | Â | Â | Â |
Good risk | 18 (6.4%) | 50 (5.5%) | 0.001 |
Intermediate risk | 148 (52.9%) | 366 (40.6%) | Â |
Adverse risk | 40 (14.3%) | 144 (16%) | Â |
Unknown risk | 74 (26.4%) | 342 (37.9%) | Â |
Disease status at transplantation | |||
CR1 | 179 (63.9%) | 522 (57.9%) | 0.023 |
CR2 + | 49 (17.5%) | 230 (25.5%) |  |
Advanced | 52 (18.6%) | 150 (16.6%) | Â |
Patient gender | Â | Â | Â |
Male | 163 (58.2%) | 430 (47.7%) | 0.002 |
Donor gender | Â | Â | Â |
Male | 187 (68.2%) | 421 (50%) | < 0.001 |
Missing | 6 | 60 | Â |
Female donor to male recipient | |||
 | 35 (12.7%) | 194 (22.2%) | < 0.001 |
Missing | 5 | 29 | Â |
HCT-CI | |||
0 | 125 (59%) | 294 (57.3%) | 0.073 |
1 or 2 | 32 (15.1%) | 112 (21.8%) | Â |
≥ 3 | 55 (25.9%) | 107 (20.9%) |  |
Missing | 68 | 389 | Â |
KPS score | |||
≥ 90 | 76 (27.1%) | 210 (23.3%) | 0.19 |
Patient CMV serostatus: positive | |||
Positive | 201 (73.6%) | 587 (66.9%) | 0.036 |
Missing | 7 | 24 | Â |
Donor CMV serostatus: positive | |||
Positive | 127 (45.8%) | 260 (35.2%) | 0.002 |
Missing | 3 | 163 | Â |
Graft source | |||
 | BM—19 (6.8%) | Single unit—408 (45.2%) |  |
 | PBSC—261 (93.2%) | Double unit—494 (54.8%) |  |
Conditioning regimen intensity | |||
MAC | 141 (50.4%) | 416 (46.1%) | 0.21 |
RIC | 139 (49.6%) | 486 (53.9%) | Â |
Type of conditioning regimen | |||
BuCy | 14 (5%) | 23 (2.5%) | < 0.001 |
BuFlu | 116 (41.4%) | 14 (1.6%) | Â |
TBF | 45 (16.1%) | 263 (29.2%) | Â |
TBI-based | 38 (13.6%) | 522 (57.9%) | Â |
Other | 67 (23.9%) | 80 (8.9%) | Â |
GVHD prophylaxisb | |||
csa + mmf | 111 (39.6%) | 638 (70.7%) |  |
tacro + mmf | 51 (18.2%) | 22 (2.4%) |  |
csa + mtx | 10 (3.6%) | 35 (3.9%) |  |
csa | 34 (12.1%) | 183 (20.3%) | Â |
tacro | 24 (8.6%) | 2 (0.2%) | Â |
siro + mmf | 14 (5%) | 8 (0.9%) |  |
other | 36 (12.9%) | 14 (1.6%) | Â |